Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment

Nicholas C. Turner(Institute of Cancer Research), François‐Clément Bidard(Inserm), Sasha McClain(AstraZeneca (Japan)), Kevin Kalinsky(Emory University), Massimo Cristofanilli(Cornell University), X. Cynthia(Washington University in St. Louis), Wolfgang Janni(Grace (United States)), Cynthia Huang Bartlett(Pfizer (United States)), Giampaolo Bianchini(Vita-Salute San Raffaele University), Erica L. Mayer(Harvard University), Stephen Chia(BC Cancer Agency), Stephen B. Fox(Peter MacCallum Cancer Centre), Xiaochun Liu(AstraZeneca (United States)), Yeon Hee Park(Samsung Medical Center), Hiroji Iwata(Aichi Cancer Center)
Future Oncology
March 1, 2023
10.2217/fon-2022-1196
Cited by 78

Related Papers

The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k